Stay Informed About Key Developments for Our Company

The Latest Updates as They Happen

As a valued partner in our shared success, you should be the first to know what’s happening across our company. The articles and announcements below offer a comprehensive glimpse into the recent developments that shape our business and growth strategies.

 

Subscribe To Our Latest Investor News

News Highlights
December 02, 2020

Bayer establishes Cell and Gene Therapy Platform to accelerate pharmaceutical innovation

READ MORE
November 9, 2020

Bayer submits marketing authorization applications for finerenone in the U.S. and the EU

READ MORE
November 3, 2020
Challenging Third Quarter

Group Outlook Confirmed

READ MORE
October 27, 2020

The U.S. EPA announces new 5-year registration for XtendiMax® herbicide

READ MORE
AD HOC

Discover Bayer’s Latest Ad Hoc Releases

READ MORE
Explore All
1 - 10of about 279 News
1 - 10of about 279 News
December 02, 2020
Bayer establishes Cell and Gene Therapy Platform to accelerate pharmaceutical innovation
READ MORE
December 01, 2020
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN ANY JURISDICTION IN WHICH SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL
Bayer announces placement of Elanco shares for gross proceeds of 1.6 billion U.S. dollars at completion
READ MORE
November 17, 2020
Not intended for U.S. and UK Media - Late-Breaking Data from subgroup analysis of Phase III FIDELIO-DKD study presented at the American Heart Association (AHA) Scientific Sessions 2020
Finerenone showed consistent benefits on cardiovascular outcomes in patients with chronic kidney disease and type 2 diabetes with or without history of cardiovascular disease
READ MORE
November 13, 2020
Not intended for U.S. and UK Media
Positive CHMP opinion for extension of rivaroxaban marketing authorization to treat venous thromboembolism (VTE) in children
READ MORE
November 12, 2020
Metagenomi closes USD 65 million Series A financing led by Leaps by Bayer and Humboldt Fund
READ MORE
November 09, 2020
Not intended for U.S. and UK Media
Bayer submits marketing authorization applications for finerenone in the U.S. and the EU for patients with chronic kidney disease and type 2 diabetes
READ MORE
November 03, 2020
Bayer:
Challenging third quarter – Group outlook confirmed
READ MORE
October 27, 2020
The U.S. EPA announces new 5-year registration for XtendiMax® herbicide, Bayer’s low-volatility dicamba product
READ MORE
October 27, 2020
Bayer appoints Dr. Christian Rommel as new Head of Pharmaceuticals Research and Development
READ MORE
October 26, 2020
Bayer acquires Asklepios BioPharmaceutical to broaden innovation base in cell and gene therapy
READ MORE
1 - 10of about 279 News
1 - 10of about 279 News